vs
高露洁棕榄（CL）与Leidos（LDOS）财务数据对比。点击上方公司名可切换其他公司
高露洁棕榄的季度营收约是Leidos的1.2倍（$5.2B vs $4.2B），Leidos净利率更高（7.8% vs -0.7%，领先8.5%），高露洁棕榄同比增速更快（5.8% vs -3.5%），高露洁棕榄自由现金流更多（$1.3B vs $452.0M），过去两年Leidos的营收复合增速更高（3.1% vs 1.6%）
高露洁棕榄是总部位于美国纽约市曼哈顿中城公园大道的跨国消费品企业，主营家居清洁、医疗护理、个人护理、宠物护理等品类产品的生产、分销及相关服务，旗下产品行销全球多地，在日用消费领域拥有广泛的市场认可度。
Leidos Holdings, Inc.是总部位于美国弗吉尼亚州雷斯顿的企业，业务覆盖国防、航空、信息技术、生物医学研究领域，提供科研、工程、系统集成及技术服务。其前身为科学应用国际公司（SAIC），2016年8月与洛克希德·马丁旗下IT业务板块合并，成为国防行业规模最大的IT服务提供商。
CL vs LDOS — 直观对比
营收规模更大
CL
是对方的1.2倍
$4.2B
营收增速更快
CL
高出9.3%
-3.5%
净利率更高
LDOS
高出8.5%
-0.7%
自由现金流更多
CL
多$824.0M
$452.0M
两年增速更快
LDOS
近两年复合增速
1.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.2B | $4.2B |
| 净利润 | $-36.0M | $327.0M |
| 毛利率 | 60.2% | 17.4% |
| 营业利润率 | 1.7% | 11.3% |
| 净利率 | -0.7% | 7.8% |
| 营收同比 | 5.8% | -3.5% |
| 净利润同比 | -104.9% | 15.1% |
| 每股收益（稀释后） | $-0.04 | $2.54 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLLDOS
| Q1 26 | — | $4.2B | ||
| Q4 25 | $5.2B | $4.4B | ||
| Q3 25 | $5.1B | $4.2B | ||
| Q2 25 | $5.1B | $4.2B | ||
| Q1 25 | $4.9B | $4.3B | ||
| Q4 24 | $4.9B | — | ||
| Q3 24 | $5.0B | $4.2B | ||
| Q2 24 | $5.1B | $4.1B |
净利润CLLDOS
| Q1 26 | — | $327.0M | ||
| Q4 25 | $-36.0M | $367.0M | ||
| Q3 25 | $735.0M | $391.0M | ||
| Q2 25 | $743.0M | $363.0M | ||
| Q1 25 | $690.0M | $284.0M | ||
| Q4 24 | $738.0M | — | ||
| Q3 24 | $737.0M | $364.0M | ||
| Q2 24 | $731.0M | $322.0M |
毛利率CLLDOS
| Q1 26 | — | 17.4% | ||
| Q4 25 | 60.2% | 18.0% | ||
| Q3 25 | 59.4% | 18.0% | ||
| Q2 25 | 60.1% | 17.5% | ||
| Q1 25 | 60.8% | 15.6% | ||
| Q4 24 | 60.3% | — | ||
| Q3 24 | 61.1% | 17.8% | ||
| Q2 24 | 60.6% | 16.6% |
营业利润率CLLDOS
| Q1 26 | — | 11.3% | ||
| Q4 25 | 1.7% | 12.0% | ||
| Q3 25 | 20.6% | 13.5% | ||
| Q2 25 | 21.1% | 12.5% | ||
| Q1 25 | 21.9% | 9.7% | ||
| Q4 24 | 21.5% | — | ||
| Q3 24 | 21.2% | 12.4% | ||
| Q2 24 | 21.6% | 11.6% |
净利率CLLDOS
| Q1 26 | — | 7.8% | ||
| Q4 25 | -0.7% | 8.2% | ||
| Q3 25 | 14.3% | 9.2% | ||
| Q2 25 | 14.5% | 8.6% | ||
| Q1 25 | 14.1% | 6.5% | ||
| Q4 24 | 14.9% | — | ||
| Q3 24 | 14.6% | 8.7% | ||
| Q2 24 | 14.5% | 7.8% |
每股收益（稀释后）CLLDOS
| Q1 26 | — | $2.54 | ||
| Q4 25 | $-0.04 | $2.82 | ||
| Q3 25 | $0.91 | $3.01 | ||
| Q2 25 | $0.91 | $2.77 | ||
| Q1 25 | $0.85 | $2.10 | ||
| Q4 24 | $0.89 | — | ||
| Q3 24 | $0.90 | $2.68 | ||
| Q2 24 | $0.89 | $2.37 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $1.1B |
| 总债务越低越好 | $7.8B | $4.6B |
| 股东权益账面价值 | $54.0M | $4.9B |
| 总资产 | $16.3B | $13.5B |
| 负债/权益比越低杠杆越低 | 145.17× | 0.94× |
8季度趋势，按日历期对齐
现金及短期投资CLLDOS
| Q1 26 | — | $1.1B | ||
| Q4 25 | $1.4B | $974.0M | ||
| Q3 25 | $1.3B | $930.0M | ||
| Q2 25 | $1.2B | $842.0M | ||
| Q1 25 | $1.1B | $943.0M | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.2B | $1.2B | ||
| Q2 24 | $1.1B | $823.0M |
总债务CLLDOS
| Q1 26 | — | $4.6B | ||
| Q4 25 | $7.8B | $4.6B | ||
| Q3 25 | — | $5.0B | ||
| Q2 25 | — | $5.0B | ||
| Q1 25 | — | $4.1B | ||
| Q4 24 | $7.0B | — | ||
| Q3 24 | — | $4.1B | ||
| Q2 24 | — | $4.1B |
股东权益CLLDOS
| Q1 26 | — | $4.9B | ||
| Q4 25 | $54.0M | $4.9B | ||
| Q3 25 | $856.0M | $4.7B | ||
| Q2 25 | $702.0M | $4.3B | ||
| Q1 25 | $363.0M | $4.4B | ||
| Q4 24 | $212.0M | — | ||
| Q3 24 | $435.0M | $4.6B | ||
| Q2 24 | $123.0M | $4.5B |
总资产CLLDOS
| Q1 26 | — | $13.5B | ||
| Q4 25 | $16.3B | $13.5B | ||
| Q3 25 | $17.5B | $13.5B | ||
| Q2 25 | $17.5B | $13.2B | ||
| Q1 25 | $16.6B | $13.1B | ||
| Q4 24 | $16.0B | — | ||
| Q3 24 | $16.8B | $13.3B | ||
| Q2 24 | $16.5B | $12.9B |
负债/权益比CLLDOS
| Q1 26 | — | 0.94× | ||
| Q4 25 | 145.17× | 0.94× | ||
| Q3 25 | — | 1.07× | ||
| Q2 25 | — | 1.18× | ||
| Q1 25 | — | 0.92× | ||
| Q4 24 | 33.04× | — | ||
| Q3 24 | — | 0.88× | ||
| Q2 24 | — | 0.92× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.5B | $495.0M |
| 自由现金流经营现金流 - 资本支出 | $1.3B | $452.0M |
| 自由现金流率自由现金流/营收 | 24.4% | 10.8% |
| 资本支出强度资本支出/营收 | 3.4% | 1.0% |
| 现金转化率经营现金流/净利润 | — | 1.51× |
| 过去12个月自由现金流最近4个季度 | $3.6B | — |
8季度趋势，按日历期对齐
经营现金流CLLDOS
| Q1 26 | — | $495.0M | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.3B | $711.0M | ||
| Q2 25 | $884.0M | $58.0M | ||
| Q1 25 | $600.0M | $299.0M | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.2B | $656.0M | ||
| Q2 24 | $990.0M | $374.0M |
自由现金流CLLDOS
| Q1 26 | — | $452.0M | ||
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.1B | $680.0M | ||
| Q2 25 | $776.0M | $36.0M | ||
| Q1 25 | $476.0M | $213.0M | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.0B | $633.0M | ||
| Q2 24 | $873.0M | $351.0M |
自由现金流率CLLDOS
| Q1 26 | — | 10.8% | ||
| Q4 25 | 24.4% | — | ||
| Q3 25 | 21.6% | 16.1% | ||
| Q2 25 | 15.2% | 0.9% | ||
| Q1 25 | 9.7% | 4.9% | ||
| Q4 24 | 21.9% | — | ||
| Q3 24 | 20.5% | 15.2% | ||
| Q2 24 | 17.3% | 8.5% |
资本支出强度CLLDOS
| Q1 26 | — | 1.0% | ||
| Q4 25 | 3.4% | — | ||
| Q3 25 | 3.0% | 0.7% | ||
| Q2 25 | 2.1% | 0.5% | ||
| Q1 25 | 2.5% | 2.0% | ||
| Q4 24 | 3.7% | — | ||
| Q3 24 | 2.7% | 0.6% | ||
| Q2 24 | 2.3% | 0.6% |
现金转化率CLLDOS
| Q1 26 | — | 1.51× | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.72× | 1.82× | ||
| Q2 25 | 1.19× | 0.16× | ||
| Q1 25 | 0.87× | 1.05× | ||
| Q4 24 | 1.72× | — | ||
| Q3 24 | 1.58× | 1.80× | ||
| Q2 24 | 1.35× | 1.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CL
| Other | $3.0B | 58% |
| Pet Nutrition | $1.2B | 23% |
| Oral Personal And Home Care | $1.0B | 20% |
LDOS
| US Do D And US Intelligence Community | $1.4B | 32% |
| Cost Reimbursement And Fixed Price Incentive Fee | $1.0B | 24% |
| Commercial And International Segment | $609.0M | 15% |
| Defense Systems Segment | $546.0M | 13% |
| Other | $358.0M | 9% |
| Time And Materials And Fixed Price Level Of Effort | $295.0M | 7% |
| Commercial And Non US Customers | $38.0M | 1% |
